Advik Laboratories, now MPS Pharmaa, reported no revenue for the June quarter and a net loss of Rs 23.8 lakh. Drug manufacturing licenses are pending renewal, operations are suspended, and trading is restricted due to unpaid BSE listing fees.
Advik Laboratories (MPS Pharmaa) Logs Zero Revenue, Rs 23.8 Lakh Loss
Advik Laboratories, now operating as MPS Pharmaa Limited, reported zero revenue from operations for the quarter ending June 30, 2026. The company also posted a net loss of Rs 23.80 lakh for the same period. ## What just happened MPS Pharmaa's financials reveal a stark situation with no income generated during the quarter. The company's drug manufacturing licenses are pending renewal with the Food & Drugs Administration (FDA), leading to suspended production activities. This operational halt directly impacts its ability to generate revenue. ## Why this matters Shareholders are facing a company with no operational revenue and ongoing losses. The suspension of drug manufacturing and pending license renewals indicate a prolonged period of inactivity. Furthermore, the company's default on BSE listing fees since FY 2021-22 has led to restricted trading, severely limiting stock liquidity. ## The backstory Advik Laboratories' struggle to maintain operations and meet regulatory requirements has been ongoing. The company's inability to pay annual listing fees for the BSE since FY 2021-22 has resulted in its stock being relegated to a weekly trade-for-trade basis. ## What changes now Management has applied for the renewal of drug manufacturing licenses and is seeking buyers for new business deals. However, significant financial and operational hurdles remain before production can resume. ## Risks to watch Key risks include the company's continued inability to generate revenue, persistent losses, and unresolved auditor qualifications regarding investments and capital work-in-progress. The unresolved listing fee default also poses a significant governance risk. ## Peer comparison [No reliable peer comparison data is available from the filing.] ## Context metrics (time-bound) - Net loss for the quarter ended June 30, 2026, stood at Rs 23.80 lakh. - This compares to a net loss of Rs 22.01 lakh for the same quarter last year (June 30, 2025). - Investments valued at Rs 53.80 lakh lack fair value determination and physical verification. - Stalled capital work-in-progress assets are valued at Rs 2.12 crore. ## What to track next Investors should monitor the progress of the FDA license renewal process, any developments in securing buyers for new business, and the company's efforts to clear outstanding BSE listing fees to resolve trading restrictions.
